239 related articles for article (PubMed ID: 22069350)
1. Ocular onchocerciasis: current management and future prospects.
Babalola OE
Clin Ophthalmol; 2011; 5():1479-91. PubMed ID: 22069350
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
Abegunde AT; Ahuja RM; Okafor NJ
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
[TBL] [Abstract][Full Text] [Related]
3. Research for new drugs for elimination of onchocerciasis in Africa.
Kuesel AC
Int J Parasitol Drugs Drug Resist; 2016 Dec; 6(3):272-286. PubMed ID: 27693536
[TBL] [Abstract][Full Text] [Related]
4. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
[TBL] [Abstract][Full Text] [Related]
5. Assessment and monitoring of onchocerciasis in Latin America.
Rodríguez-Pérez MA; Unnasch TR; Real-Najarro O
Adv Parasitol; 2011; 77():175-226. PubMed ID: 22137585
[TBL] [Abstract][Full Text] [Related]
6. Moxidectin: an oral treatment for human onchocerciasis.
Milton P; Hamley JID; Walker M; Basáñez MG
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
[TBL] [Abstract][Full Text] [Related]
7. Control of onchocerciasis.
Boatin BA; Richards FO
Adv Parasitol; 2006; 61():349-94. PubMed ID: 16735169
[TBL] [Abstract][Full Text] [Related]
8. Final report of the Conference on the eradicability of Onchocerciasis.
Dadzie Y; Neira M; Hopkins D
Filaria J; 2003 Feb; 2(1):2. PubMed ID: 12605722
[TBL] [Abstract][Full Text] [Related]
9. Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol.
Wanji S; Nji TM; Hamill L; Dean L; Ozano K; Njouendou AJ; Abong RA; Obie ED; Amuam A; Ekanya R; Ndongmo WPC; Ndzeshang BL; Fung EG; Nnamdi DB; Nkimbeng DA; Teghen S; Kah E; Piotrowski H; Forrer A; Khan JAM; Woode ME; Niessen L; Watson V; Njoumemi Z; Murdoch ME; Thomson R; Theobald S; Enyong P; Turner JD; Taylor MJ
Parasit Vectors; 2019 Dec; 12(1):574. PubMed ID: 31801631
[TBL] [Abstract][Full Text] [Related]
10. The Onchocerciasis Elimination Program for the Americas (OEPA).
Sauerbrey M
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
[TBL] [Abstract][Full Text] [Related]
11. The Mectizan Donation Program (MDP).
Thylefors B
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():39-44. PubMed ID: 18718154
[TBL] [Abstract][Full Text] [Related]
12. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
[TBL] [Abstract][Full Text] [Related]
13. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.
Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH
BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085
[TBL] [Abstract][Full Text] [Related]
15. Towards the elimination of onchocerciasis.
Thylefors B; Alleman M
Ann Trop Med Parasitol; 2006 Dec; 100(8):733-46. PubMed ID: 17227651
[TBL] [Abstract][Full Text] [Related]
16. Importance of ivermectin to human onchocerciasis: past, present, and the future.
Cupp EW; Mackenzie CD; Unnasch TR
Res Rep Trop Med; 2011; 2():81-92. PubMed ID: 30881181
[TBL] [Abstract][Full Text] [Related]
17. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
18. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
19. Onchocerciasis and other eye problems in developing countries: a challenge for optometrists.
Berger IB; Nnadozie J
J Am Optom Assoc; 1993 Oct; 64(10):699-702. PubMed ID: 8245390
[TBL] [Abstract][Full Text] [Related]
20. Ivermectin for onchocercal eye disease (river blindness).
Ejere HO; Schwartz E; Wormald R; Evans JR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
